We increase production of COVID-19 drugs

In an effort to save lives during the health crisis caused by COVID-19, At #Vitalis we work tirelessly increasing our production to generate a greater reach of our medicines in the Latin American market.
Since the start of the pandemic we have delivered 79,4 million units in 43 products, where the greatest increase is reflected in anesthetics and sedatives with a 153% growth versus the previous year, followed by corticosteroids with a 38% and antibiotics with a 6%; medications that have been vital to the care of patients affected by COVID-19.

This is our commitment to the health of all.